« Back

PDF Version

AVI BioPharma to Present Business Strategy at Cowen and Company's 27th Annual Health Care Conference

03/13/07 9:02 AM EDT

PORTLAND, Ore.--(BUSINESS WIRE)--March 13, 2007--AVI BioPharma, Inc. (Nasdaq:AVII), announced that Chief Executive Officer Denis R. Burger, Ph.D., will be presenting an update on the company's business strategy and clinical development today at Cowen and Company LLC's 27th Annual Health Care Conference. Dr. Burger's presentation will begin at 9:30 a.m. at The Boston Marriott Copley Place Hotel.

About AVI BioPharma

AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using third-generation NEUGENE(R) antisense drugs. AVI's lead NEUGENE antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis, cancer and polycystic kidney disease. In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to combat disease by targeting single-stranded RNA viruses, including West Nile virus, hepatitis C virus, dengue virus, Ebola virus and influenza A virus. AVI has introduced a NEUGENE-based exon-skipping technology called ESPRIT therapy. More information about AVI is available on the company's Web site at http://www.avibio.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.


    CONTACT: AVI BioPharma, Inc.
             Michael Hubbard, hubbard@avibio.com
             503-227-0554
             or
             AVI Investor Contacts:
             Lippert/Heilshorn & Associates Inc.
             Brandi Floberg, bfloberg@lhai.com
             Jody Cain, jcain@lhai.com
             310-691-7100
             or
             AVI Press Contact:
             Waggener Edstrom Worldwide Bioscience and Healthcare
             Practice
             Jenny Moede, jmoede@waggeneredstrom.com
             503-443-7000

    SOURCE: AVI BioPharma, Inc.

 

This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.